Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT)
- 1 July 2003
- journal article
- review article
- Published by Elsevier BV in Urologic Oncology: Seminars and Original Investigations
- Vol. 21 (4), 282-291
- https://doi.org/10.1016/s1078-1439(03)00057-7
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Combination Chemotherapy with Paclitaxel, Estramustine and Carboplatin for Hormone Refractory Prostate CancerJournal of Urology, 2002
- Nomogram for Overall Survival of Patients With Progressive Metastatic Prostate Cancer After CastrationJournal of Clinical Oncology, 2002
- Randomized Study of Three Different Doses of Suramin Administered With a Fixed Dosing Schedule in Patients With Advanced Prostate Cancer: Results of Intergroup 0159, Cancer and Leukemia Group B 9480Journal of Clinical Oncology, 2002
- A STRUCTURED DEBATE: IMMEDIATE VERSUS DEFERRED ANDROGEN SUPPRESSION IN PROSTATE CANCER—EVIDENCE FOR DEFERRED TREATMENTJournal of Urology, 2001
- Living With Treatment Decisions: Regrets and Quality of Life Among Men Treated for Metastatic Prostate CancerJournal of Clinical Oncology, 2001
- A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinomaCancer, 2000
- Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 StudyJournal of Clinical Oncology, 1999
- Post-therapy Serum Prostate-Specific Antigen Level and Survival in Patients With Androgen-Independent Prostate CancerJNCI Journal of the National Cancer Institute, 1999
- How Much Can We Rely on the Level of Prostate-Specific Antigen as an End Point for Evaluation of Clinical Trials? A Word of Caution!JNCI Journal of the National Cancer Institute, 1996
- Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapyCancer, 1992